Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours.

Antiproliferative treatment of patients with metastatic endocrine gastroenteropancreatic tumours (GEP) is based mainly on chemotherapeutic protocols whereby drug toxicity is a major handicap. Octreotide is the first choice in the control of hormone mediated symptoms. From retrospective and a few pro...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Arnold, R, Trautmann, M E, Creutzfeldt, W, Benning, R, Benning, M, Neuhaus, C, Jürgensen, R, Stein, K, Schäfer, H, Bruns, C, Dennler, H J
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 1996
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC1383075/
https://ncbi.nlm.nih.gov/pubmed/8675099
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia